SOCIETE PHARMACEUTIQUE ANTILLAISE : revenue, balance sheet and financial ratios

In 2025, SOCIETE PHARMACEUTIQUE ANTILLAISE achieves revenue of 255.3 M€. Revenue is growing positively over 9 years (CAGR: +2.2%). Vs 2024, growth of +11% (229.7 M€ -> 255.3 M€). After deducting consumption (226.9 M€), gross margin stands at 28.4 M€, i.e. a rate of 11%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 7.5 M€, representing 2.9% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 4.9 M€, i.e. 1.9% of revenue. This profit can be retained or distributed to shareholders.

The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 2.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

The liquidity ratio (= Current assets / Current liabilities) stands at 194.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 19.5x. Operating income very largely covers interest expenses: high safety margin.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 47 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 38 days. The company must finance 9 days of gap between collections and payments. Inventory turnover is 67 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 92 days of revenue, i.e. 64.9 M€ to permanently finance.

Based on 124 transactions of similar company sales (all years), the value of SOCIETE PHARMACEUTIQUE ANTILLAISE is estimated at 19 747 202 € (range 10 395 102€ - 61 921 678€). With an EBITDA of 7 461 112€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.